LYRA Stock Overview
A clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$6.79 |
| 52 Week Low | US$0.16 |
| Beta | -0.036 |
| 11 Month Change | -27.82% |
| 3 Month Change | -42.44% |
| 1 Year Change | -94.09% |
| 33 Year Change | -96.79% |
| 5 Year Change | n/a |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Shareholder Returns
| LYRA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.1% | -1.4% | 0.3% |
| 1Y | -94.1% | 10.8% | 31.1% |
Return vs Industry: LYRA underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: LYRA underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| LYRA volatility | |
|---|---|
| LYRA Average Weekly Movement | 13.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LYRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LYRA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 109 | Maria Palasis | lyratherapeutics.com |
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps.
Lyra Therapeutics, Inc. Fundamentals Summary
| LYRA fundamental statistics | |
|---|---|
| Market cap | US$11.65m |
| Earnings (TTM) | -US$97.61m |
| Revenue (TTM) | US$1.47m |
8.1x
P/S Ratio-0.1x
P/E RatioIs LYRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYRA income statement (TTM) | |
|---|---|
| Revenue | US$1.47m |
| Cost of Revenue | US$49.67m |
| Gross Profit | -US$48.20m |
| Other Expenses | US$49.41m |
| Earnings | -US$97.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | -3,276.61% |
| Net Profit Margin | -6,635.76% |
| Debt/Equity Ratio | 0% |
How did LYRA perform over the long term?
See historical performance and comparison